echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Two injections of Sichuan Creed Pharmaceuticals continue to enter administrative approval

    Two injections of Sichuan Creed Pharmaceuticals continue to enter administrative approval

    • Last Update: 2021-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the Sodium Valproate Injection and Micuronium Chloride Injection, which were reported for production by Sichuan Creed Pharmaceuticals under the new registration classification, have entered the administrative examination and approval stage.
    At present, no generic drugs have been approved for the listing of these two products in China.
    According to data from Meinenet, the market size of sodium valproate in China's public medical institutions exceeds 2 billion yuan.

    Micuronium chloride is a benzyl isoquinoline compound.
    It is a highly selective, short-acting, non-depolarizing neuromuscular blocker.
    It has the characteristics of quick recovery after action and can be used as an auxiliary drug for general anesthesia.
    Relax the skeletal muscles to facilitate tracheal intubation and mechanical ventilation.

    At present, only GlaxoSmithKline’s Micuronium Chloride injection is on sale in China.
    It is a national health insurance category B product.
    In recent years, it has been used in urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as China Public Medical Agency) terminal sales are not outstanding.

    Production status of new classification of micuronium injection

    Source: Mi Nei Net Consistency Evaluation Database

    According to data from Minaiwang, two companies, Guangdong Jiabo Pharmaceutical and Sichuan Creed Pharmaceuticals, have submitted applications for the listing of micuronium chloride injections under the new classification.
    Sichuan Creed Pharmaceuticals' products have entered the administrative examination and approval stage and are expected to win the first imitation.

    Sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug that can competitively inhibit Y-aminobutyric acid transaminase, and is effective for various types of minor seizures, myogenic epilepsy, localized grand mal seizures, grand mal seizures and mixed epilepsy.
    , Clinically used for various epilepsy that other anti-epileptic drugs are ineffective.

    According to data from Menet.
    com, in 2019, the sales of terminal sodium valproate in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 2 billion yuan, and the growth rate in the first half of 2020 declined slightly .
    At present, the main varieties of sodium valproate on the market in China include sodium valproate for injection, sodium valproate sustained-release tablets, sodium valproate tablets, etc.
    There is no sodium valproate injection on the market.

    New classification of valproate injection

    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database

    At present, many companies have submitted applications for the listing of sodium valproate injection with imitation of three categories.
    Among them, the products of Hebei Renheyikang Pharmaceutical and Sichuan Creed Pharmaceutical have entered the administrative examination and approval stage.

    Source: Minet database

    Note: The statistics are as of March 25.
    If there are any omissions, please correct me!

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.